These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 36680930)

  • 61. Prognostic comparison of proliferation markers and World Health Organization 1973/2004 grades in urothelial carcinomas of the urinary bladder.
    Mangrud OM; Gudlaugsson E; Skaland I; Tasdemir I; Dalen I; van Diermen B; Baak JP; Janssen EA
    Hum Pathol; 2014 Jul; 45(7):1496-503. PubMed ID: 24796506
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer.
    Ikeda J; Ohe C; Yoshida T; Kuroda N; Saito R; Kinoshita H; Tsuta K; Matsuda T
    Pathol Int; 2021 Mar; 71(3):173-182. PubMed ID: 33503295
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Efficacy of BCG for non-muscle invasive bladder cancer following nephroureterectomy for upper tract urothelial carcinoma.
    Massari M; O'Malley P; Benidir T; Su LM; Gao H; Crispen PL
    Urol Oncol; 2024 Sep; 42(9):289.e7-289.e12. PubMed ID: 38802293
    [TBL] [Abstract][Full Text] [Related]  

  • 64. WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach.
    Otto W; Breyer J; Herdegen S; Eder F; Bertz S; May M; Mayr R; Lausenmeyer EM; Denzinger S; van Rhijn BW; Burger M; Hartmann A
    Int Urol Nephrol; 2017 Mar; 49(3):431-437. PubMed ID: 28035618
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.
    Ochoa AE; Choi W; Su X; Siefker-Radtke A; Czerniak B; Dinney C; McConkey DJ
    Oncotarget; 2016 Dec; 7(49):80164-80174. PubMed ID: 27845906
    [TBL] [Abstract][Full Text] [Related]  

  • 67. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
    Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
    Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular Pathologic Subtyping of Urothelial Bladder Carcinoma in Young Patients.
    Shelekhova KV; Krykow KA; Mescherjakov IA; Mitin NP
    Int J Surg Pathol; 2019 Aug; 27(5):483-491. PubMed ID: 30854907
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.
    Dadhania V; Zhang M; Zhang L; Bondaruk J; Majewski T; Siefker-Radtke A; Guo CC; Dinney C; Cogdell DE; Zhang S; Lee S; Lee JG; Weinstein JN; Baggerly K; McConkey D; Czerniak B
    EBioMedicine; 2016 Oct; 12():105-117. PubMed ID: 27612592
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Subcategorization of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens for Predicting Progression.
    Budina A; Farahani SJ; Lal P; Nayak A
    Arch Pathol Lab Med; 2022 Sep; 146(9):1131-1139. PubMed ID: 34871364
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.
    Reddy OL; Cates JM; Gellert LL; Crist HS; Yang Z; Yamashita H; Taylor JA; Smith JA; Chang SS; Cookson MS; You C; Barocas DA; Grabowska MM; Ye F; Wu XR; Yi Y; Matusik RJ; Kaestner KH; Clark PE; DeGraff DJ
    Am J Pathol; 2015 May; 185(5):1385-95. PubMed ID: 25907831
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Snail immunohistochemical overexpression correlates to recurrence risk in non-muscle invasive bladder cancer: results from a longitudinal cohort study.
    Santi R; Cai T; Nobili S; Galli IC; Amorosi A; Comperat E; Nesi G
    Virchows Arch; 2018 Apr; 472(4):605-613. PubMed ID: 29525824
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predicting progression of bladder urothelial carcinoma using microRNA expression.
    Rosenberg E; Baniel J; Spector Y; Faerman A; Meiri E; Aharonov R; Margel D; Goren Y; Nativ O
    BJU Int; 2013 Nov; 112(7):1027-34. PubMed ID: 23387295
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.
    Tadin T; Krpina K; Štifter S; Babarović E; Jonjić N
    Pathol Res Pract; 2014 May; 210(5):279-84. PubMed ID: 24553301
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.
    de Jong JJ; Liu Y; Boorjian SA; Bivalacqua TJ; Porten SP; Wheeler T; Davicioni E; Svatek RS; Boormans JL; Black PC; Lotan Y; Gibb EA
    J Urol; 2020 Aug; 204(2):239-246. PubMed ID: 32074006
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study.
    Dawood S; Hu R; Homes MD; Collins LC; Schnitt SJ; Connolly J; Colditz GA; Tamimi RM
    Breast Cancer Res Treat; 2011 Feb; 126(1):185-92. PubMed ID: 20711652
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer.
    Otto W; Rubenwolf PC; Burger M; Fritsche HM; Rößler W; May M; Hartmann A; Hofstädter F; Wieland WF; Denzinger S
    BMC Cancer; 2012 Oct; 12():459. PubMed ID: 23043286
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
    Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
    Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.